Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

People with high diastolic blood pressure more likely to have cognitive impairment

High blood pressure is linked to memory problems in people over 45, according to research published in the August 25, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Scientists have identified the inflammatory process as the common soil in a diverse range of chronic degenerative diseases. The news, recently reported in the LA Times article, discusses how foods like cherries may help rheumatoid arthritis or avoidance of gluten may fight off psoriasis.

24 Aug 2009

UCLA's Laboratory of Neuro Imaging awarded $1.9 million NIH ARRA grant

UCLA researchers have received 80 American Recovery and Reinvestment Act of 2009 (Recovery Act) grants totaling $19.4 million from the National Institutes of Health thus far. UCLA's largest NIH ARRA grant to date was $1.9 million, awarded to UCLA's Laboratory of Neuro Imaging (LONI), which is dedicated to creating scientific approaches to mapping how the brain is structured and how it works.

24 Aug 2009

The California Chronic Care Coalition launches new website to share information on chronic conditions

The California Chronic Care Coalition (CCCC) continues to advance its work toward meaningful and responsible health care reform with the launching of its consumer website: www.chroniccareca.org. Designed to help build a healthier California, the website is aimed at the more than 16 million Californians with chronic conditions such as Asthma, Diabetes, Alzheimer’s Heart disease, Epilepsy and Multiple Sclerosis.

24 Aug 2009

Nervous system integrity could play a central role in preventing prion diseases

A new study shows that nervous system integrity and axonal properties may play a key role in prion diseases. The findings, from researchers at the Rudolf Virchow Center and the Institute of Virology of the University of W-rzburg, expand our understanding of the development of prion disease and suggest novel targets for therapeutic and diagnostic approaches in its early stages.

24 Aug 2009

Greg Peet elected as Chairman of Vigil Health Solutions

Vigil Health Solutions Inc. ("Vigil") (TSX VENTURE:VGL) is pleased to announce the completion of its 2009 AGM. Shareholders elected Greg Peet (as Chairman), Troy Griffiths, Harry Jaako, Stephen Martin and Tanner Philp as Directors of Vigil. KPMG LLP was appointed auditors of Vigil. The shareholders also approved an amendment to the Omnibus Plan to increase the number of Common Shares reserved for issuance under the Omnibus Plan to 15,000,000 Common Shares (being approximately 15.0% of the total outstanding Common Shares of the Company).

24 Aug 2009

Real Americans share experiences, common need for patient-centric reform

Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

21 Aug 2009

Physicians lack knowledge of off-label drug use and FDA approval status

In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This mistaken belief could encourage them to prescribe these drugs, despite the lack of scientific evidence supporting such use.

21 Aug 2009

Research reveals brain activity networks of Alzheimer's disease affected patients become more random and unstructured

Different types of dementia show dissimilar changes in brain activity. A network mapping technique described in the open access journal BMC Neuroscience has been applied to EEG data obtained from patients with Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD, a less common type of dementia with more prominent behavioral symptoms).

21 Aug 2009

Mesenchymal stem cells repair human brain

There is no known cure for neurodegenerative diseases such as Huntington's, Alzheimer's and Parkinson's. But new hope, in the form of stem cells created from the patient's own bone marrow, can be found ― and literally seen ― in laboratories at Tel Aviv University.

20 Aug 2009

The Dilemma of an Aging Society research study classifies elder people into four groups

A lot of discussion has centered on proposed legislation regarding "death panels" and end of life counseling.

20 Aug 2009

Arzoxifene phase 3 study results reported by Lilly

Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

19 Aug 2009

Orient Pharma granted commercialization rights for a drug candidate by DURECT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).

19 Aug 2009

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

19 Aug 2009

Fruit flies' fat-store levels can be measured and controlled by brain neuron manipulation

A team of scientists from the California Institute of Technology (Caltech) have pinpointed two groups of neurons in fruit fly brains that have the ability to sense and manipulate the fly's fat stores in much the same way as do neurons in the mammalian brain.

19 Aug 2009

George Rehm and David Mahoney joins Adamas' Board of Directors

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, the company announced the election of George M. Rehm, Managing Partner of aeris CAPITAL AG, and David L. Mahoney, a private equity investor, to the company's Board of Directors.

19 Aug 2009

Mediterranean-type diet and exercise lowers Alzheimer's risk

Both being more physically active and adhering to a Mediterranean-type diet appears to be associated with reduced Alzheimer's risk, according to a new report in the August 12, 2009 issue of the Journal of the American Medical Association (JAMA).

18 Aug 2009

Smoking increases risk for brain shrinkage in multiple sclerosis

People who smoke and have multiple sclerosis (MS) may be at increased risk of brain shrinkage and increased brain lesions related to the disease, according to a study published in the August 18, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Smoking has already been linked to an increased risk of developing MS.

18 Aug 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

People with high diastolic blood pressure more likely to have cognitive impairment

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

UCLA's Laboratory of Neuro Imaging awarded $1.9 million NIH ARRA grant

The California Chronic Care Coalition launches new website to share information on chronic conditions

Nervous system integrity could play a central role in preventing prion diseases

Greg Peet elected as Chairman of Vigil Health Solutions

Real Americans share experiences, common need for patient-centric reform

Physicians lack knowledge of off-label drug use and FDA approval status

Research reveals brain activity networks of Alzheimer's disease affected patients become more random and unstructured

Mesenchymal stem cells repair human brain

The Dilemma of an Aging Society research study classifies elder people into four groups

Arzoxifene phase 3 study results reported by Lilly

Orient Pharma granted commercialization rights for a drug candidate by DURECT

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Fruit flies' fat-store levels can be measured and controlled by brain neuron manipulation

George Rehm and David Mahoney joins Adamas' Board of Directors

Mediterranean-type diet and exercise lowers Alzheimer's risk

Smoking increases risk for brain shrinkage in multiple sclerosis

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in